Venetoclax

The role of venetoclax in previously treated WM including BTK inhibitor-exposed patients

Determining the optimal dose of induction therapy for patients with AML

Implications of RAS mutational status in subsets of patients with newly diagnosed AML

Low-dose azacitidine and venetoclax as maintenance therapy in patients with AML

Potential therapeutic targets in subsets of PTCL

Ongoing challenges and unanswered questions in the field of AML

The optimal sequencing of novel therapies in mantle cell lymphoma

AML in 2022 and beyond

Standard of care treatment approaches in MCL and the role of chemotherapy-free regimens

The role of glasdegib in AML

The role of inflammatory signaling pathways in lower-risk MDS

Promising agents under investigation for the treatment of MDS and ongoing trials in this space

The importance of genomic testing in CLL in the era of novel therapies

The importance of TP53 & IGHV testing before treatment initiation in CLL

SELECT-AML-1: tamibarotene with venetoclax and azacitidine in patients with RARA-positive AML

Insights into the BRUIN CLL-322 trial